Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO NOVUM 1 50 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO NOVUM 1 50 28.
ORTHO TRI-CYCLEN 21 vs ORTHO-NOVUM 1/50 28
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
Combination oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via estrogen and progestin, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial structure.
Prevention of pregnancy
Prevention of pregnancy
One tablet daily for 21 days, followed by 7 days of placebo, then repeat. Each tablet contains 0.180 mg norgestimate and 0.035 mg ethinyl estradiol (days 1–7), 0.215 mg/0.035 mg (days 8–14), and 0.250 mg/0.035 mg (days 15–21). Oral route.
One tablet (1 mg norethindrone/50 mcg mestranol) orally once daily for 21 days, followed by 7 days of placebo tablets (inactive) for a 28-day cycle.
None Documented
None Documented
Norgestimate: ~24 hours (terminal); ethinyl estradiol: ~17 hours (terminal). Steady-state achieved within 5-7 days; clinical significance: missed doses may increase contraceptive failure risk.
Norethindrone: 5-12 h (mean 8 h); Mestranol: 12-24 h (mean 18 h); steady-state reached within 5-7 days
Norgestimate: hydrolyzed to norelgestromin and norgestrel; metabolized by CYP3A4, CYP2C9, and CYP2C19. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation.
Ethinyl estradiol metabolized via CYP3A4; mestranol (prodrug converted to ethinyl estradiol) and norethindrone metabolized via hepatic reduction and conjugation.
Renal: ~70% (metabolites, primarily glucuronide and sulfate conjugates of norgestimate and ethinyl estradiol); Fecal: ~30% (biliary elimination of unchanged drug and metabolites).
Renal: ~50-60% as metabolites; fecal: ~30-40% as metabolites; biliary: <10%
Norgestimate: ~99% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin; norethindrone (active metabolite) binds with similar high affinity.
Norethindrone: 96-98% (SHBG, albumin); Mestranol: 97-99% (albumin, SHBG with lower affinity)
Norgestimate: Vd ~6-8 L/kg; ethinyl estradiol: Vd ~3-5 L/kg. Large Vd indicates extensive tissue distribution including breast, uterine, and hepatic tissues; clinical relevance: potential for drug interactions (e.g., enzyme inducers).
Norethindrone: 1.5-2.5 L/kg; Mestranol: 0.9-1.5 L/kg; indicates extensive tissue distribution
Oral: Norgestimate ~75% (first-pass metabolism limits bioavailability); ethinyl estradiol ~40-60% (substantial first-pass effect).
Oral: norethindrone ~64%; mestranol ~40-70% (first-pass metabolism)
No specific dose adjustment is provided in manufacturer labeling; use with caution in patients with renal impairment. GFR-based adjustments are not established.
No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Insufficient data for severe impairment (CrCl <30 mL/min); avoid use due to potential for fluid retention and hypertension.
Contraindicated in patients with hepatic disease or hepatocellular carcinoma. Child-Pugh class B or C: contraindicated. Child-Pugh class A: use with caution, no specific dose adjustment defined.
Contraindicated in severe hepatic disease (Child-Pugh C) or acute liver disease. For mild to moderate impairment (Child-Pugh A or B), use with caution; monitor liver function, no specific dose adjustment guidelines available.
Safety and efficacy established in postmenarchal females; dosing is same as adult: one tablet daily for 21 days. Weight-based dosing not applicable.
Not indicated in prepubertal girls. Postmenarchal adolescents: same as adult dosing; initiate after menarche and once growth complete.
Not indicated for use in postmenopausal women. No specific considerations available.
Not indicated for postmenopausal women; no geriatric-specific dosing. Use with caution in older women due to increased risk of thromboembolism and cardiovascular events.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Use is contraindicated in women over 35 years who smoke.
["Thrombotic disorders (e.g., thrombophlebitis, pulmonary embolism, stroke, myocardial infarction)","Hepatic disease (including hepatic adenoma or carcinoma)","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism disturbances","Headache (including migraine with focal symptoms)","Uterine bleeding irregularities"]
Increased risk of thromboembolic disorders, venous thromboembolism (VTE), arterial thrombosis, myocardial infarction, stroke, hepatic neoplasia, and gallbladder disease. Regular monitoring of blood pressure, glucose, and lipid profiles recommended.
["Known or suspected pregnancy","Current or history of thromboembolic disorders (e.g., DVT, PE)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal genital bleeding","Hepatic adenoma or carcinoma, or active liver disease","Hypersensitivity to any component","Smoking in women over 35 years","Uncontrolled hypertension","Diabetes with vascular involvement","Migraine with aura if >35 years","Major surgery with prolonged immobilization"]
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; pregnancy; hepatic adenoma or carcinoma; jaundice with prior pill use; hypersensitivity to components; women over 35 who smoke.
Data Pending Review
Data Pending Review
No specific food restrictions; however, grapefruit juice may increase estrogen levels (minor interaction). Avoid St. John's wort, which can reduce contraceptive efficacy.
No significant food interactions. Grapefruit juice may slightly increase estrogen exposure; avoid excessive intake. Taking with food may reduce nausea.
First trimester: Risk of congenital anomalies (limb defects, neural tube defects) based on case reports; overall risk low. Second/third trimester: Possible increased risk of intrauterine growth restriction and preterm birth. Postnatal: Potential for jaundice and transient hormonal effects in neonates.
Pregnancy category X. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects due to progestin and estrogen exposure. Second and third trimesters: Risk of fetal genital abnormalities (e.g., hypospadias, clitoral hypertrophy), low birth weight, and potential long-term metabolic effects. Use contraindicated in pregnancy.
Contraindicated in breastfeeding due to estrogens reducing milk production and quality. Limited data; M/P ratio not established. Alternative methods preferred.
Contraindicated during breastfeeding. Norethindrone and mestranol/metabolites are excreted in breast milk; M/P ratio not established. May reduce milk production and quality, and expose infant to hormonal effects. Recommend alternative contraception.
No dose adjustments needed as drug is contraindicated during pregnancy. Discontinue immediately upon confirmed pregnancy; pharmacokinetic changes not applicable.
No indication for use in pregnancy; contraindicated. If inadvertent use occurs, discontinue immediately. No pharmacokinetic data to support dose adjustments as drug should not be administered during pregnancy.
Category C
Category C
ORTHO TRI-CYCLEN 21 contains norgestimate and ethinyl estradiol; it is a triphasic oral contraceptive with varying hormone doses across 21 active pills. Its progestin component has low androgenicity, making it suitable for patients with acne or hirsutism. Monitor for thromboembolic risk, especially in smokers over 35. Missed pill management: if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception and consider emergency contraception.
ORTHO-NOVUM 1/50 28 is a monophasic oral contraceptive containing mestranol 50 µg (a prodrug of ethinyl estradiol) and norethindrone 1 mg. Due to higher estrogen dose, it poses increased risk of venous thromboembolism, especially in smokers over 35. It may reduce the efficacy of lamotrigine. Use with caution in patients with hypertension or liver disease.
Take one pill daily at the same time for 21 days, then 7 placebo pills.Use backup contraception (e.g., condoms) for the first 7 days of initial use.Common side effects: nausea, breast tenderness, breakthrough bleeding; these often improve after 2-3 cycles.Report signs of blood clots: leg pain/swelling, chest pain, sudden shortness of breath, severe headache.Smoking increases blood clot risk; do not smoke while using this medication.If severe vomiting or diarrhea occurs within 4 hours after taking a pill, consider it missed and follow missed pill instructions.
Take one tablet daily at the same time, following the package directions for the 28-day regimen.If you miss a pill, follow the instructions in the package insert; use backup contraception if needed.Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often resolve after a few cycles.This medication does not protect against HIV or other sexually transmitted infections.Smoking while using this pill increases your risk of serious cardiovascular side effects; do not smoke.Contact your provider if you experience leg pain, chest pain, shortness of breath, severe headache, or vision changes.